ANAPTYSBIO INC (ANABV) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ANABV SEC filings page.
ANAPTYSBIO INC (ANABV) reported $232.4M in revenue over the twelve months to Mar 31, 2026, up 107.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a sharp operating turnaround, but thin equity leaves the business heavily leveraged.
Revenue more than doubled from$91.3M to$234.6M while R&D declined. That pairing, alongside the swing from a negative to positive operating margin, points to scale and spending mix rather than clearly demonstrated price effects.
The cash-conversion picture improved: operating profit of
The balance sheet remains thinly capitalized: total liabilities of
Financial Health Signals
ANAPTYSBIO INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ANAPTYSBIO INC passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
ANAPTYSBIO INC reported a net loss of $13.2M while generating $19.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
ANAPTYSBIO INC generated $25.6M in revenue in Q1 2026. This represents a decrease of 8.0% from the same quarter a year earlier. Against the prior quarter it is down 76.4%.
ANAPTYSBIO INC's EBITDA was -$34.5M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 26.0% from the same quarter a year earlier.
ANAPTYSBIO INC reported -$52.9M in net income in Q1 2026. This represents a decrease of 34.5% from the same quarter a year earlier. Against the prior quarter it is down 206.6%.
ANAPTYSBIO INC earned -$1.84 per diluted share (EPS) in Q1 2026. This represents a decrease of 43.8% from the same quarter a year earlier.
Cash & Balance Sheet
ANAPTYSBIO INC recorded an outflow of $25.9M in free cash flow in Q1 2026, representing a cash shortfall after capex. This represents a decrease of 141.6% from the same quarter a year earlier. Against the prior quarter it is down 126.5%.
ANAPTYSBIO INC held $248.5M in cash as of Q1 2026; long-term debt is not reported for that period.
Not reported for Q1 2026.
Margins & Returns
ANAPTYSBIO INC's ROE was -414.9% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 299.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 548.2 percentage points.
Not reported for Q1 2026.
Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
ANAPTYSBIO INC invested $34.0M in research and development in Q1 2026. This represents a decrease of 17.5% from the same quarter a year earlier. Against the prior quarter it is up 33.0%.
ANAPTYSBIO INC repurchased no shares in Q1 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
ANAPTYSBIO INC invested $17K in capex in Q1 2026, funding long-term assets and infrastructure. This represents a decrease of 51.4% from the same quarter a year earlier. Against the prior quarter it is up 1600.0%.
ANABV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6M-8.0% | $108.2M+151.1% | $76.3M+154.3% | $22.3M+102.9% | $27.8M+286.8% | $43.1M+378.8% | $30.0M+804.7% | $11.0M+217.1% |
| R&D Expenses | $34.0M-17.5% | $25.6M-40.0% | $31.4M-25.6% | $37.8M-9.9% | $41.2M+11.2% | $42.6M+27.0% | $42.2M+36.7% | $42.0M+27.6% |
| SG&A Expenses | $26.2M+85.4% | $15.8M+54.9% | $10.2M-3.3% | $10.6M+14.1% | $14.1M+14.5% | $10.2M-0.8% | $10.6M+3.8% | $9.3M-13.0% |
| Operating Income | -$34.6M-25.8% | $66.9M+791.8% | $34.7M+252.5% | -$26.2M+35.1% | -$27.5M+34.7% | -$9.7M+77.0% | -$22.8M+39.7% | -$40.3M-0.4% |
| EBITDA | -$34.5M-26.0% | N/A | N/A | N/A | -$27.4M+34.8% | N/A | N/A | N/A |
| Income Tax | $40K-9.1% | $81K+1450.0% | $0 | $39K+333.3% | $44K | -$6K | $0 | $9K |
| Net Income | -$52.9M-34.5% | $49.6M+327.8% | $15.1M+146.0% | -$38.6M+17.2% | -$39.3M+10.5% | -$21.8M+48.4% | -$32.9M+11.9% | -$46.7M-17.1% |
| EPS (Basic) | -$1.84-43.8% | N/A | $0.54+147.4% | -$1.34+21.6% | -$1.28+22.0% | N/A | -$1.14+19.1% | -$1.71-14.0% |
| EPS (Diluted) | -$1.84-43.8% | N/A | $0.52+145.6% | -$1.34+21.6% | -$1.28+22.0% | N/A | -$1.14+19.1% | -$1.71-14.0% |
| Diluted Shares (Avg) | 29M-6.4% | N/A | 29M+0.4% | 29M+5.3% | 31M+14.3% | N/A | 29M+8.8% | 27M+2.7% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
ANABV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $329.7M-21.9% | $364.4M-24.7% | $353.1M-28.4% | $335.3M-21.6% | $422.1M+4.0% | $483.8M+7.0% | $493.4M+1.3% | $427.4M-17.4% |
| Current Assets | $316.1M-12.9% | $350.3M-18.9% | $330.6M-26.3% | $291.9M-20.5% | $363.1M-2.5% | $431.9M+6.2% | $448.7M+4.8% | $367.4M-16.2% |
| Cash & Equivalents | $248.5M+151.9% | $238.2M+93.5% | $109.8M-42.7% | $44.3M-38.3% | $98.6M+83.7% | $123.1M+242.2% | $191.6M+628.6% | $71.8M+104.0% |
| Total Liabilities | $316.9M-18.3% | $327.2M-20.8% | $382.5M-6.5% | $380.0M-9.0% | $388.0M+8.4% | $413.0M+13.4% | $409.1M+11.5% | $417.5M+13.3% |
| Current Liabilities | $41.7M-5.3% | $38.6M-15.0% | $38.1M-13.2% | $35.5M-12.1% | $44.0M+36.3% | $45.4M+21.3% | $43.9M+12.0% | $40.4M-2.9% |
| Non-Current Liabilities | $275.2M-20.0% | $288.6M-21.5% | $344.4M-5.7% | $344.5M-8.7% | $344.0M+5.6% | $367.5M+12.5% | $365.2M+11.4% | $377.1M+15.3% |
| Total Equity | $12.7M-62.5% | $37.2M-47.5% | -$29.4M-134.9% | -$44.7M-552.8% | $34.0M-28.8% | $70.9M-19.6% | $84.4M-29.9% | $9.9M-93.3% |
| Retained Earnings | -$825.4M-3.4% | -$772.6M-1.7% | -$822.2M-11.5% | -$837.3M-18.8% | -$798.7M-21.4% | -$759.3M-23.6% | -$737.5M-29.0% | -$704.7M-31.8% |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
ANABV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$25.9M-142.2% | $98.0M+247.0% | -$27.4M-171.1% | -$40.2M-88.7% | -$10.7M+71.3% | -$66.7M-94.1% | -$10.1M+72.3% | -$21.3M+16.1% |
| Depreciation & Amortization | $130K-11.0% | N/A | N/A | N/A | $146K-10.4% | N/A | N/A | N/A |
| Stock-Based Compensation | $14.2M+55.0% | N/A | $9.2M+11.8% | $9.2M+22.5% | $9.2M-9.5% | N/A | $8.2M+4.9% | $7.5M-10.5% |
| Capital Expenditures | $17K-51.4% | $1K-99.6% | $12K-65.7% | $39K+18.2% | $35K+29.6% | $263K-6.1% | $35K-78.4% | $33K-82.6% |
| Free Cash Flow | -$25.9M-141.6% | $98.0M+246.4% | -$27.4M-170.3% | -$40.3M-88.6% | -$10.7M+71.2% | -$66.9M-93.3% | -$10.1M+72.4% | -$21.4M+16.6% |
| Investing Cash Flow | $35.0M+135.6% | $73.5M+350.0% | $103.3M+76.2% | $36.4M+1590.7% | $14.8M-78.4% | -$29.4M-159.8% | $58.6M+91.3% | -$2.4M+88.1% |
| Financing Cash Flow | $1.2M+104.2% | -$43.1M-256.5% | -$10.4M-114.6% | -$50.5M-220.5% | -$28.6M-109.7% | $27.6M+634.3% | $71.2M+2418.7% | $41.9M+410.5% |
| Share Buybacks | $0-100.0% | $3.4M+642.1% | $9.7M | $51.1M | $4.4M | $456K | $0 | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid.
ANABV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -135.5% | 61.8%+84.2pp | 45.5%+121.3pp | -117.5% | -99.2% | -22.4% | -75.8% | -367.5% |
| Net Margin | -206.9% | 45.8%+96.4pp | 19.8% | -173.5% | -141.6% | -50.5% | -109.4% | -425.3% |
| Return on Equity | -414.9%-299.3pp | 133.3%+164.1pp | N/A | N/A | -115.6%-23.6pp | -30.7%+17.2pp | -38.9%-8.0pp | -472.3%-445.5pp |
| Return on Assets | -16.0%-6.7pp | 13.6%+18.1pp | 4.3%+10.9pp | -11.5%-0.6pp | -9.3%+1.5pp | -4.5%+4.8pp | -6.7%+1.0pp | -10.9%-3.2pp |
| Current Ratio | 7.58-0.7x | 9.07-0.4x | 8.68-1.5x | 8.22-0.9x | 8.25-3.3x | 9.51-1.4x | 10.23-0.7x | 9.09-1.4x |
| Debt-to-Equity | 24.86+13.5x | 8.79+3.0x | N/A | N/A | 11.41+3.9x | 5.83+1.7x | 4.85+1.8x | 42.26+39.8x |
| Asset Turnover | 0.080.0x | 0.30+0.2x | 0.22+0.2x | 0.070.0x | 0.070.0x | 0.09+0.1x | 0.06+0.1x | 0.030.0x |
| FCF Margin | -101.5% | 90.5% | -35.9%-2.1pp | -180.9% | -38.7% | -155.3% | -33.7% | -194.6% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Where ANAPTYSBIO INC Ranks
Frequently Asked Questions
What is ANAPTYSBIO INC's annual revenue?
ANAPTYSBIO INC (ANABV) reported $234.6M in total revenue for fiscal year 2025. This represents a 157.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ANAPTYSBIO INC's revenue growing?
ANAPTYSBIO INC (ANABV) revenue grew by 157.0% year-over-year, from $91.3M to $234.6M in fiscal year 2025.
Is ANAPTYSBIO INC profitable?
No, ANAPTYSBIO INC (ANABV) reported a net income of -$13.2M in fiscal year 2025, with a net profit margin of -5.6%.
What is ANAPTYSBIO INC's EBITDA?
ANAPTYSBIO INC (ANABV) had EBITDA of $48.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ANAPTYSBIO INC's operating margin?
ANAPTYSBIO INC (ANABV) had an operating margin of 20.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is ANAPTYSBIO INC's net profit margin?
ANAPTYSBIO INC (ANABV) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is ANAPTYSBIO INC's return on equity (ROE)?
ANAPTYSBIO INC (ANABV) has a return on equity of -35.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ANAPTYSBIO INC's free cash flow?
ANAPTYSBIO INC (ANABV) generated $19.6M in free cash flow during fiscal year 2025. This represents a 114.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ANAPTYSBIO INC's operating cash flow?
ANAPTYSBIO INC (ANABV) generated $19.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are ANAPTYSBIO INC's total assets?
ANAPTYSBIO INC (ANABV) had $364.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ANAPTYSBIO INC's capital expenditures?
ANAPTYSBIO INC (ANABV) invested $87K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ANAPTYSBIO INC spend on research and development?
ANAPTYSBIO INC (ANABV) invested $136.0M in research and development during fiscal year 2025.
What is ANAPTYSBIO INC's current ratio?
ANAPTYSBIO INC (ANABV) had a current ratio of 9.07 as of fiscal year 2025, which is generally considered healthy.
What is ANAPTYSBIO INC's debt-to-equity ratio?
ANAPTYSBIO INC (ANABV) had a debt-to-equity ratio of 8.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ANAPTYSBIO INC's return on assets (ROA)?
ANAPTYSBIO INC (ANABV) had a return on assets of -3.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ANAPTYSBIO INC's Piotroski F-Score?
ANAPTYSBIO INC (ANABV) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ANAPTYSBIO INC's earnings high quality?
ANAPTYSBIO INC (ANABV) reported a net loss of $13.2M while generating $19.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.